News

FDA staff cuts are already impacting regulatory work, Biotech leaders warn
A group of biotech CEOs, investors, and patient advocates have urged Senate HELP Committee Chairman Bill Cassidy (R-LA) to ...
Zacks Investment Research on MSN4h
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?
Beam Therapeutics Inc. (BEAM) shares ended the last trading session 12.6% higher at $16.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease
Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...
Beam Therapeutics (BEAM) Gets a Buy from Scotiabank
Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.
Beam Therapeutics presents additional data for BEAM-302 in AATD
Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin ...
KLP Kapitalforvaltning AS Makes New Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)
KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...
Mitsubishi UFJ Asset Management Co. Ltd. Has $244,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)
Mitsubishi UFJ Asset Management Co. Ltd. lowered its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 9.4% ...